Kliniken Suedostbayern AG
- Address
- lock Available on a paid plan
Hemic and Lymphatic Diseases
At Kliniken Suedostbayern AG the hematology‑oncology‑palliative care department concentrates on lymphoma research, with a particular focus on older adults who cannot tolerate full‑dose chemotherapy.
- Combination therapy with a BTK inhibitor
- Reduced‑dose chemotherapy strategies
- Outcomes in patients over 80 years of age
- Safety profiling in frail populations
Five investigators are leading efforts to improve progression‑free survival for patients with Diffuse large B‑cell lymphoma by testing a new drug‑plus‑chemo regimen.
Neoplasms
The site also addresses a broad spectrum of high‑grade B‑cell lymphomas, including rare variants such as primary mediastinal large B‑cell lymphoma and ALK‑positive large B‑cell lymphoma.
- Molecular characterization of MYC/BCL2 rearranged lymphomas
- Evaluation of novel targeted agents
- Clinical assessment of lymphoma subtypes with viral association
- Integration of diagnostic biomarkers
Through two active trials, the team aims to refine treatment options and expand therapeutic choices for patients with aggressive neoplasms across Europe.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 15 of 49 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 48 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
- 1Pfizer Inc.2active
lock +9 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Pfizer Inc.2trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Kliniken Suedostbayern AG
lock Showing 1 of 17 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized, Open-label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults with Untreated Diffuse Large B-Cell Lymphoma (ARCHED/GLA 2022-1) | University Of Saarland | Phase III | Recruiting | Apr 2023 | — |
IMP list
lock Showing 1 of 49 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Capecitabine | 3 | Unknown | 2019-12-04 | 2025-04-01 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.